Mr. Damien McCallion:

To illustrate the point on the medical side, there is a number of roles. There is the logistics of being able to manage all the smears, which is relatively easy to develop, but, on the medical side, there are approximately 1.5 consultants in the public system. We need a number of other consultants but we must look at a model that allows them to operate in other aspects of pathology. One is unlikely to attract people into a role with that specialty on its own. We are looking at how we develop that. The other challenge, which I mentioned earlier, relates to the screeners themselves. Cytology is becoming a much reduced profession. The current model will reduce the requirement for cytoscreeners by approximately 80%. In some UK trusts at the moment, for instance, a significant backlog is emerging where screeners are leaving because of difficulties relating to their future career prospects, and laboratories are being closed. We are trying to capture some of that if we can to help us with our current problems, even in the short term.